TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial of Intermittent Preventive Treatment and Home Based Management of Malaria in a Rural Area of The Gambia
Brief Summary: Malaria in African countries remains an important cause of mortality and morbidity among young children. The global malaria control strategies include prompt treatment with an effective antimalarial drug, vector control using ITNs or curtains, indoor residual spraying (IRS), and intermittent preventive treatment. However, individually these interventions provide only imperfect protection. Thus, there is a need to investigate whether additional control measures provide added benefit in reducing mortality and morbidity. Therefore, 1312 children under 5 years of age living in villages and hamlets near Farafenni, The Gambia, which form part of the rural Farafenni Demographic Surveillance system (FDSS) in North Bank Region(NBR) were randomly allocated to receive IPTc or placebo from village health workers based in primary health care villages. Treatment with a single dose of sulfadoxine /pyrimethamine plus three doses of amodiaquine or placebo was given to all study subjects at monthly intervals on three occasions during the months of September, October and November. In addition, VHWs were trained to administer treatment with coartem to children if they develop symptoms compatible with malaria during the malaria transmission season. The primary end point was the incidence of clinical attacks of malaria detected during the study.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment with AQ+ SP | Intervention Type: DRUG; Name: Intermittent preventive treatment with AQ+ SP; Assigned to Arm(s): 2
B: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo
C: Intervention Type: DRUG; Name: Intrarectal quinine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Sulfadoxine/pyrimethamine and artesunate; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial of Intermittent Preventive Treatment and Home Based Management of Malaria in a Rural Area of The Gambia
Brief Summary: Malaria in African countries remains an important cause of mortality and morbidity among young children. The global malaria control strategies include prompt treatment with an effective antimalarial drug, vector control using ITNs or curtains, indoor residual spraying (IRS), and intermittent preventive treatment. However, individually these interventions provide only imperfect protection. Thus, there is a need to investigate whether additional control measures provide added benefit in reducing mortality and morbidity. Therefore, 1312 children under 5 years of age living in villages and hamlets near Farafenni, The Gambia, which form part of the rural Farafenni Demographic Surveillance system (FDSS) in North Bank Region(NBR) were randomly allocated to receive IPTc or placebo from village health workers based in primary health care villages. Treatment with a single dose of sulfadoxine /pyrimethamine plus three doses of amodiaquine or placebo was given to all study subjects at monthly intervals on three occasions during the months of September, October and November. In addition, VHWs were trained to administer treatment with coartem to children if they develop symptoms compatible with malaria during the malaria transmission season. The primary end point was the incidence of clinical attacks of malaria detected during the study.


Options:
A: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo
B: Intervention Type: BEHAVIORAL; Name: Provision of antimalarial treatment at home; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Microscopy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clinical diagnosis for malaria | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Rapid diagnostic test | Intervention Type: PROCEDURE; Name: Rapid diagnostic test; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Microscopy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Clinical diagnosis for malaria; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Rapid diagnostic test for malaria | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Rapid diagnostic test for malaria | Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial of Intermittent Preventive Treatment and Home Based Management of Malaria in a Rural Area of The Gambia
Brief Summary: Malaria in African countries remains an important cause of mortality and morbidity among young children. The global malaria control strategies include prompt treatment with an effective antimalarial drug, vector control using ITNs or curtains, indoor residual spraying (IRS), and intermittent preventive treatment. However, individually these interventions provide only imperfect protection. Thus, there is a need to investigate whether additional control measures provide added benefit in reducing mortality and morbidity. Therefore, 1312 children under 5 years of age living in villages and hamlets near Farafenni, The Gambia, which form part of the rural Farafenni Demographic Surveillance system (FDSS) in North Bank Region(NBR) were randomly allocated to receive IPTc or placebo from village health workers based in primary health care villages. Treatment with a single dose of sulfadoxine /pyrimethamine plus three doses of amodiaquine or placebo was given to all study subjects at monthly intervals on three occasions during the months of September, October and November. In addition, VHWs were trained to administer treatment with coartem to children if they develop symptoms compatible with malaria during the malaria transmission season. The primary end point was the incidence of clinical attacks of malaria detected during the study.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment (SP and amodiaquine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Intermittent preventive treatment (SP and amodiaquine); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo
C: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
D: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment with AQ+ SP | Intervention Type: DRUG; Name: Intermittent preventive treatment with AQ+ SP; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Zinc Supplementation, Provided as Either a Liquid Zinc Solution or Dispersible Tablets, on Plasma Zinc Concentration Among Young Burkinabe Children
Brief Summary: The study aims to compare the effects of two different formulations of zinc supplements on plasma zinc concentrations among young Burkinabe children.


Options:
A: Arm Label: Zinc syrup; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Liquid zinc syrup | Arm Label: Zinc tablet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Liquid placebo supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Liquid zinc syrup; Assigned to Arm(s): Zinc syrup | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc tablet; Assigned to Arm(s): Zinc tablet | Intervention Type: DIETARY_SUPPLEMENT; Name: Liquid placebo supplement; Assigned to Arm(s): Placebo
B: Arm Label: Fe, Zn, Fe+Zn, Placebo; Type: N/A; Interventions: N/A
C: Arm Label: Zinc fortified group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc fortified food, Other: Placebo supplement | Arm Label: Non-fortified group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo supplement, Dietary Supplement: Non-fortified food | Arm Label: Zinc supplement group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc supplement, Dietary Supplement: Non-fortified food | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc fortified food; Assigned to Arm(s): Zinc fortified group | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc supplement; Assigned to Arm(s): Zinc supplement group | Intervention Type: OTHER; Name: Placebo supplement; Assigned to Arm(s): Non-fortified group, Zinc fortified group | Intervention Type: DIETARY_SUPPLEMENT; Name: Non-fortified food; Assigned to Arm(s): Non-fortified group, Zinc supplement group
D: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Partially-blind Phase III Randomised Trial of Fulvestrant (Faslodex) With or Without Concomitant Anastrozole (Arimidex) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-steroidal Aromatase Inhibitors
Brief Summary: A partially-blind, randomised, multicentre phase III trial of Faslodex plus concomitant Arimidex versus Faslodex plus Arimidex-Placebo versus exemestane in postmenopausal locally advanced / metastatic breast cancer patients who have progressed on NSAIs. Randomisation to Faslodex ± Arimidex / Arimidex-Placebo or exemestane will be open (1:1:1). For Faslodex treated patients the randomisation to Arimidex or Arimidex-Placebo will be double-blind.


Options:
A: Arm Label: Arm I (anastrozole, gefitinib); Type: EXPERIMENTAL; Interventions: Drug: anastrozole, Drug: gefitinib, Other: laboratory biomarker analysis | Arm Label: Arm II (fulvestrant, gefitinib); Type: EXPERIMENTAL; Interventions: Drug: gefitinib, Drug: fulvestrant, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): Arm I (anastrozole, gefitinib) | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Arm I (anastrozole, gefitinib), Arm II (fulvestrant, gefitinib) | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): Arm II (fulvestrant, gefitinib) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (anastrozole, gefitinib), Arm II (fulvestrant, gefitinib)
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anastrozole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fulvestrant, Drug: Anastrozole | Intervention Type: DRUG; Name: Fulvestrant; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Anastrozole; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fulvestrant, Drug: anastrozole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: fulvestrant | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: exemestane | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): 3
D: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: anastrozole, Drug: fulvestrant | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): Arm II

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Intermediate Care Clinics for Diabetes
Brief Summary: The aim of this trial is to assess the effectiveness of intermediate care clinics for diabetes, compared to usual care.


Options:
A: Arm Label: access to intermediate care clinics; Type: EXPERIMENTAL; Interventions: Other: intermediate care clinics (ICCs) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: intermediate care clinics (ICCs); Assigned to Arm(s): access to intermediate care clinics
B: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Peer counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Assigned a peer counselor | Arm Label: Financial incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentives | Intervention Type: BEHAVIORAL; Name: Assigned a peer counselor; Assigned to Arm(s): Peer counseling | Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): Financial incentives
D: Arm Label: close follow-up by nurse; Type: N/A; Interventions: Behavioral: Secondary prevention intervention trial | Arm Label: standard follow up; Type: N/A; Interventions: Behavioral: standard follow up | Intervention Type: BEHAVIORAL; Name: Secondary prevention intervention trial; Assigned to Arm(s): close follow-up by nurse | Intervention Type: BEHAVIORAL; Name: standard follow up; Assigned to Arm(s): standard follow up

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Intermediate Care Clinics for Diabetes
Brief Summary: The aim of this trial is to assess the effectiveness of intermediate care clinics for diabetes, compared to usual care.


Options:
A: Arm Label: Assistance with Pain Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Assistance with Pain treatment | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assistance with Pain treatment; Assigned to Arm(s): Assistance with Pain Treatment
B: Arm Label: access to intermediate care clinics; Type: EXPERIMENTAL; Interventions: Other: intermediate care clinics (ICCs) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: intermediate care clinics (ICCs); Assigned to Arm(s): access to intermediate care clinics
C: Arm Label: Collaborative depression care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): Collaborative depression care
D: Arm Label: Depression CAREPATH; Type: EXPERIMENTAL; Interventions: Other: Depression CAREPATH | Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Depression CAREPATH; Assigned to Arm(s): Depression CAREPATH | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients Homozygous for the F508del Mutation? A Randomized, Double Blind Placebo-controlled Study.
Brief Summary: The purpose of this study is to investigate within a short delay the effect of nasal instillation of Miglustat on nasal potential difference in cystic fibrosis patients homozygous for the F508del mutation.


Options:
A: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA
B: Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Miglustat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Miglustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Miglustat; Assigned to Arm(s): Miglustat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ataluren (PTC124®); Type: EXPERIMENTAL; Interventions: Drug: Ataluren (PTC124®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren (PTC124®); Assigned to Arm(s): Ataluren (PTC124®) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Part A: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM, Drug: IVA | Arm Label: Part B: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM, Drug: IVA | Intervention Type: DRUG; Name: LUM; Assigned to Arm(s): Part A: LUM/IVA, Part B: LUM/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: LUM/IVA, Part B: LUM/IVA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preoperative Oral Supplementation With Carbohydrate and Branched-chain Amino Acid-enriched Nutrient Improves Postoperative Quality of Life in Patients Undergoing a Hepatectomy
Brief Summary: The aims of this study are (1) to study the benefit of branched-chain amino acids enriched nutrient-mixture by analyzing a variety of clinical parameter, including laboratory data, the duration of hospitalization after the surgery, and (2) To investigate the postoperative quality of life (QOL) in receiving peri-operatively branched-chain amino acids enriched nutrient-mixture in patients who undergone the hepatic management for hepatocellular carcinoma (HCC) with chronic liver disease.


Options:
A: Arm Label: Aminolaban EN; Type: EXPERIMENTAL; Interventions: Drug: Aminoleban EN | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Drug: Aminoleban EN | Intervention Type: DRUG; Name: Aminoleban EN; Assigned to Arm(s): Aminolaban EN, Control
B: Arm Label: 1; Type: OTHER; Interventions: Procedure: Standard Care | Arm Label: 2; Type: OTHER; Interventions: Procedure: Fast Track care | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Fast Track care; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Intravenous nutrition with glucose and amino acids | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Intravenous nutrition with glucose and amino acids. | Intervention Type: OTHER; Name: Intravenous nutrition with glucose and amino acids; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Intravenous nutrition with glucose and amino acids.; Assigned to Arm(s): 2
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Traditional management | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fast track patient management | Intervention Type: PROCEDURE; Name: Fast track patient management; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Traditional management; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preoperative Oral Supplementation With Carbohydrate and Branched-chain Amino Acid-enriched Nutrient Improves Postoperative Quality of Life in Patients Undergoing a Hepatectomy
Brief Summary: The aims of this study are (1) to study the benefit of branched-chain amino acids enriched nutrient-mixture by analyzing a variety of clinical parameter, including laboratory data, the duration of hospitalization after the surgery, and (2) To investigate the postoperative quality of life (QOL) in receiving peri-operatively branched-chain amino acids enriched nutrient-mixture in patients who undergone the hepatic management for hepatocellular carcinoma (HCC) with chronic liver disease.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard ERAS group | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide), Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Intervention Type: DRUG; Name: Post operative laxation (Magnesium Oxide); Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Preoperative metabolic conditioning postoperative nutritional supplementation; Assigned to Arm(s): 3, 4 | Intervention Type: OTHER; Name: Standard ERAS group; Assigned to Arm(s): 1
B: Arm Label: Aminolaban EN; Type: EXPERIMENTAL; Interventions: Drug: Aminoleban EN | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Drug: Aminoleban EN | Intervention Type: DRUG; Name: Aminoleban EN; Assigned to Arm(s): Aminolaban EN, Control
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Immunonutrition | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: food for special medical purposes (FSMP) | Intervention Type: DIETARY_SUPPLEMENT; Name: Immunonutrition; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: food for special medical purposes (FSMP); Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Oral Impact® | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral Impact®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B